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Abstract:
Objective: Recent results from the Cardiovascular (CV) Trial of the Testosterone(T) 
Trials showed that T treatment of older men with low T was associated with greater 
progression of non-calcified plaque (NCP). We evaluated the effect of 
anthropometric measures and cardiovascular biomarkers on plaque progression in 
individuals in the T Trial. 
Methods: The CV part of the trial included 170 men aged 65 years or older with 
low T. Participants received T gel or placebo gel for 12 months. The primary 
outcome was change in NCP volume from baseline to 12 months, as determined by 
coronary computed tomography angiography (CCTA). We assayed several markers 
of CV risk and analyzed each marker individually in a model as predictive variables 
and change in NCP as the dependent variable.  
RESULTS: Of 170 enrollees, 138 (73 T, 65 placebo) completed the study and were 
available for the primary analysis. Of 9 markers evaluated, none showed a 
significant association with the change in NCP volume, but a significant interaction 
between treatment assignment and waist-hip ratio p-0.0014) indicated that this 
variable impacted the testosterone effect on non-calcified plaque volume.  The 
statistical model indicated that for every 0.1 change in the waist-hip ratio, the T-
induced 12-month change in non-calcified plaque volume increased by 26.96 mm3 
(95% confidence interval 7.72, 46.20).  
Conclusion: Among older men with low T treated for one year, greater waist-hip 
ratio was associated with greater NCP progression, as measured by CCTA. Other 
biomarkers and anthropometric measures did not show statistically significant 
association with plaque progression. 
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Introduction:
Lower serum testosterone concentration has been associated with adverse 
cardiovascular disease (CVD) outcomes1,2. There are conflicting reports regarding 
the effect of testosterone treatment on CVD risk. Some retrospective studies 
reported more CVD events in men taking testosterone, while others did not3-7. The 
Testosterone Trials (TTrials) comprised seven coordinated placebo-controlled 
clinical trials designed to assess the effects of testosterone treatment in older men 
who had low testosterone concentrations for no apparent reason other than age8. In
the Cardiovascular Trial, testosterone treatment for one year compared with 
placebo was associated with significantly greater progression of coronary artery 
non-calcified plaque volume measured by serial coronary computed tomography 
angiography (CCTA)9.  
Serum markers such as total cholesterol, high density lipoprotein(HDL), low density 
lipoprotein( LDL) and hemoglobin A1C, have been recognized as significant risk 
factors for developing coronary artery plaque and future CVD events10,11. There are 
contradictory reports about the association of biomarkers and extent, progression of
atherosclerosis and coronary events12-14.Inflammatory markers such as c-reactive 
protein (CRP) have been reported to be associated with plaque progression in some 
studies15,16, other reports found no association17,18. Anthropometric measures such 
as Waist-Hip ratio and Waist Circumference are predictors of myocardial infarction 
risk19,20. Abdominal obesity can lead to increases in insulin and glucose levels and is 
a central feature of metabolic syndrome. Several observational studies have shown 
link of low endogenous sex hormones and metabolic syndrome21-23.  One large cross-
sectional study reported that higher testosterone and sex hormone binding globulin 
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levels in older men were independently associated with reduced risk of metabolic 
syndrome and higher insulin sensitivity24.  
The aim of the current study is to evaluate the impact of baseline anthropometric 
measures and cardiovascular biomarkers on the progression of coronary artery 
plaque volume in the 138 men who participated in the Cardiovascular Trial of the 
TTrials.  We also assessed the interaction of anthropometric measures and 
cardiovascular biomarkers with testosterone treatment for atherosclerotic plaque 
progression.
METHODS
Study Design
The TTrials comprised seven double-blind, placebo-controlled randomized controlled
trials. The overall study design of TTrials, as well that of Cardiovascular Trial, has 
been published8,25.  To qualify for the TTrials overall, a participant had to qualify for 
at least 1 of 3 main trials (Sexual Function Trial, Physical Function Trial, and Vitality 
Trial).  Qualified men could also participate in any of other trials, if respective 
eligibility criteria were met. The participants were allocated to receive testosterone 
or placebo gel for 1 year8,9. Institutional review boards of all participating sites 
approved TTrials and Cardiovascular Trial protocols. All participants provided 
written consent. Trial conduct and participant safety was supervised by an 
independent safety and data monitoring board. 
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Participants
The TTrials included men > 65 years’ old who had symptoms and objective evidence
of low libido, physical dysfunction and/or low vitality, serum testosterone levels that
averaged < 275 ng/dL on 2 morning samples. Men who were at moderate or high 
risk for prostate cancer, who had had a myocardial infarction within the previous 3 
months, or had systolic blood pressure >160 mm Hg or diastolic blood pressure 
>100 mm Hg, were excluded8. 
Exclusion criteria specifically for the Cardiovascular Trial included  circumstances 
that either made coronary artery CT angiography (CCTA) technically unfeasible 
(inability to hold breath for 10 seconds, a prior diagnosis of tachycardia or irregular 
heart rhythm [e.g., atrial fibrillation], weight >136 kg, or history of coronary artery 
bypass graft surgery) or increased risk of performing the CCTA (estimated 
glomerular filtration rate <60 mL/min/1.73 m2 or known allergy to iodinated 
contrast)9,25.
Testosterone Treatment:
Participants were assigned to receive either testosterone as a 1 % gel in a pump 
bottle (AndroGel) or placebo gel by a double-blinded method for one year. The 
initial dose was 5 g/d and was adjusted to maintain the serum concentrations within
normal range for young men (280-873 ng/dL) measured at central laboratory (Quest
Clinical Trials) at months 1, 2, 3, 6, and 9. Whenever dose adjustments were made 
in a man receiving testosterone treatment, the dose was changed in a man 
receiving placebo as well to maintain blinding8.
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Assessments:
The concentrations of cardiovascular biomarkers were measured on serum samples 
drawn at baseline and months 3 and 12 and stored at -80 C. These assays were 
performed at the  Laboratory for Clinical Biochemistry Research, University of 
Vermont and University of Minnesota, as described previously7,9. At months 3, 6, 9, 
and 12, clinical variables were measured.
Details of coronary artery plaque volume by CCTA assessment have been 
published25.  In brief, coronary artery plaque volume was assessed by CCTA at 9 of 
the 12 TTrials clinical sites.  Pre-contrast scans for evaluation of coronary artery 
calcium density and post contrast scans for evaluation of coronary artery plaque 
volume were performed at baseline and 12 months. Scans were assessed at a 
central reading center (Harbor-UCLA Medical Center) by readers who were blinded 
both to treatment group and date of scan. Quantitative plaque assessment was 
conducted according to a  previously defined protocol26 using semi-automated 
plaque analysis software (QAngioCT Research Edition Version 2.0.5; Medis Medical 
Imaging Systems). Based on the guidelines of the Society of Cardiovascular 
Computed Tomography, 17-segment coronary artery model vessels greater than 1.5
mm were evaluated27. The volumes of four types of coronary artery plaque (low 
attenuation, fibrous-fatty, fibrous, and dense calcified) were calculated by 
Hounsfield unit threshold.  The primary outcome was change in non-calcified plaque
volume from baseline to month 12. Non-calcified plaque was defined as the sum of 
the fibrous, fibrous fatty and low attenuation plaque.  Secondary outcomes were 
change in calcified plaque volume, and change in coronary artery score.  Details of 
intra- and inter-observer variability have been published. The intra-class 
correlations (ICCs) and Coefficient of Variation (CVs) were 0.99 and 7.8 % for intra-
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observer variability respectively. ICC and CV was 0.95 and 19.9 % for inter-observer
variability respectively9.
Statistical Analyses
 The following markers were available for study: total cholesterol; non-HDL 
cholesterol; HDL; LDL; total cholesterol/HDL ratio; triglycerides; HgA1c; glucose, 
insulin; homeostatin model assessment(HOMA); d-dimer; troponin; CRP; interleukin-
6 (IL-6); weight; BMI; waist; waist/hip ratio.  We evaluated the inter-correlation of 
the baseline values of these markers, separately within groups where substantial 
inter-correlation was expected: lipid markers, metabolic markers, markers of 
inflammation, and clinical markers.  We then excluded from further study the 
marker showing correlation > 0.5 with the most other markers, and then eliminated
any marker with correlation > 0.5 with the selected marker from further 
consideration.  We retained any other markers with correlation < 0.5 with the 
selected marker.  If two markers showed high correlation with the same number of 
other markers, we selected the one with the lowest correlation with the remaining 
markers.  We also included d-dimer and troponin without testing them for 
correlation with other markers as they did not fit into the any of the 4 categories 
noted above. 
We tested each selected marker separately in a regression model, including 
treatment as a covariate as well as age (over or under 75), baseline testosterone 
(over or under 200 ng/ml) and an interaction term of the marker with treatment.  
Any variable showing a significant association with the change in plaque volume 
after adjusting for multiple comparisons using the Holm procedure28 was to be 
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included in a multivariable model, assessing all potentially predictive variables 
simultaneously.  
 Secondary analyses included testing association of the selected markers with 
change in calcified plaque volume and with coronary artery calcium score, using the
same approach as above.
Results
Of 138 men who were enrolled, 73 received testosterone treatment and 65 received
placebo. The baseline characteristics of the participants in the Cardiovascular Trial 
were previously reported (9). At baseline, the mean (SD) age was 71.2 (5.7) years.  
The majority of participants were white (81%) and had relatively high rates of 
cardiovascular risk factors, including hypertension, hyperlipidemia, obesity, and 
diabetes.  At baseline the mean BMI 30.6 (3.8) in the testosterone group and 30 
(3.5) in the placebo group; mean weight was 94 kg and the mean waist-hip ratio 
was 1.0 in each treatment group.   The calculated 10-year risk of cardiovascular 
events was relatively high as well (a mean risk of 27% [95% CI, 6.4%-47.6%] in the 
placebo group and 24% [95% CI 2.6%-45.4%] in the testosterone group. 
Of the 18 markers initially evaluated, 9 remained for further study after removing 
those that were highly correlated with other markers, as described above.  These 9 
remaining markers were HDL cholesterol, non-HDL cholesterol, D-dimer, IL-6, CRP, 
insulin, HgbA1C, weight and waist-hip ratio (Table-1). Among these 9 measures, 
only the baseline waist-hip ratio interaction with treatment showed a significant 
association with the progression of non-calcified plaque volume at 12 months, 
(Table 2, Figure 1).  Because it was the interaction term that met the threshold 
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based on the multiple comparisons adjustment (p=0.0014 compared to threshold 
value from the Holm multiple comparisons procedure of 0.0056), we evaluated 
waist-hip ratio separately for the two treatment groups.  The association was seen 
only in the testosterone group (p=0.007).  The model indicates that for every 0.1 
change in the waist-hip ratio, the effect of testosterone on the 12-month change in 
non-calcified plaque volume would increase by 26.96 mm3 (95% confidence interval 
7.72, 46.20).(The baseline values of waist-hip ratio ranged from 0.9 to 1.2). 
None of the cardiovascular risk markers were statistically significantly associated
with  change  in  calcified  plaque  or  CAC  score  when  applying  the  multiple
comparisons correction.  
DISCUSSION:
We report that in older hypo gonadal men participating in the Cardiovascular Trial of
the TTrials there was a significant association between baseline waist-hip ratio and 
progression of non-calcified coronary artery plaque volume measured by coronary 
artery CT angiography after one year of testosterone treatment.  Among men taking
testosterone, larger waist-hip ratios were associated with greater progression of 
non-calcified plaque.
There is strong association among presence of visceral adipose tissue, insulin 
sensitivity, dyslipidemia, and increase in inflammation and hypertension29,30. 
Visceral adipose tissue stores can be measured by CT, DXA or MRI but these 
modalities are too expensive and time consuming for day-to-day use 31,32. WHR is 
closely related to visceral fat  and commonly measured in clinical practice33.  Meta-
analyses of 28,114 patients from 15 prospective studies showed that for every 0.01 
increase in WHR, there was a 5 % increase in risk of future CVD events 33. Our data 
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indicate that for every 0.1 increase in waist hip ratio, there was 26 mm3 greater 
increase in progression of non-calcified plaque volume in patients treated with 
testosterone replacement therapy. 
Non-calcified plaque volumes as assessed by cardiac CCTA has been associated 
with CVD events. In a large single center trial by Zu et al34, the cumulative 
probability of 3-year major adverse cardiovascular events (including cardiac death, 
nonfatal myocardial infarction, or coronary revascularization)  increased across the 
strata for cardiac CT plaque characteristics (5.5 % for calcified plaque, 22.7% for 
non-calcified plaque, and 37.7 % for mixed plaque, p<0.001)
WHR and waist circumference, measures of central obesity or abdominal obesity, 
have been associated with reduced total testosterone levels35,36.  A mechanisms 
that may account for this inverse relationship may involve increased leptin levels 
which are hypothesized to interfere with luteinizing hormone stimulating androgen 
production and decreased SHBG in  central obesity.37  Another plausible mechanism 
of decreased testosterone in obese individuals is increased aromatase activity in 
visceral adipose tissue, which leads to higher conversion of testosterone to 
estradiol38. Androgen deprivation therapy, as given to patients with prostate cancer,
has shown to significantly increase BMI, total weight, body fat mass and decrease in
lean body mass39,40. Hence, several studies have investigated the hypothesis that 
testosterone replacement therapy may decrease visceral fat stores and improve the
metabolic profile in men. However, there are conflicting reports on effects of 
testosterone replacement on visceral fat. Some studies reported testosterone 
replacement therapy decreases visceral fat, while other showed no association41,42.  
In a study of 261 patients in a prospective longitudinal registry, testosterone 
replacement was associated with a significant reduction in obesity parameters (e.g. 
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WC, BMI) and cholesterol values over the 5-year study period43. However, 
randomized controlled clinical trials reported no impact of testosterone replacement
on weight, BMI and metabolic syndrome4144.  A previous paper from the TTrials also 
did not show any changes in WHR, WC and BMI in men treated with testosterone for
12 months compared to those treated with placebo7. 
These results are hypothesis generating and warrant further investigation of the 
interaction of visceral adipose tissue stores and testosterone treatment. To our 
knowledge, no other studies have examined the interaction of testosterone 
replacement therapy and central obesity on CVD outcomes.  The strengths of our 
trial included requiring all men to have unequivocally low testosterone at baseline, 
a placebo-controlled design and blinded central review of baseline and 12 month 
scans.  An important limitation of our study is use of a surrogate marker of heart 
disease, non-calcified plaque, and not a clinical outcome. Another limitation is that 
the results apply only to men >65 with low testosterone9. 
Furthermore, this our results may indicate a chance finding. Although we did adjust 
for multiple comparisons but there remains a possibility abovementioned cardiac 
risk factors may be related to cardiovascular events with testosterone therapy.
We conclude that among older men receiving testosterone treatment, those with 
higher vs. lower WHR may experience greater increases in noncalcified coronary 
plaque volume.  Future trials should evaluate the interaction of testosterone 
treatment and surrogate markers of abdominal obesity and visceral fat stores. 
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